Canada markets open in 6 hours 44 minutes

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
134.56-4.23 (-3.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close138.79
Bid0.00 x 1200
Ask0.00 x 1000
Day's Range130.64 - 138.60
52 Week Range76.59 - 331.68
Avg. Volume5,413,210
Market Cap10.023B
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-13.84
Earnings DateNov. 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est264.20
  • Motley Fool

    Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

    Biotech stocks are in a slump. Despite numerous wins in the high-profile areas of COVID-19 and cancer therapy, the industry has failed to excite investors this year -- as seen in the 12% year-to-date fall in the the bellwether SPDR S&P Biotech ETF. Risk-tolerant growth investors appear to be favoring other vehicles over biotech in 2021, such as the red-hot cryptocurrency Shiba Inu (CRYPTO: SHIB), electric-vehicle giant Tesla (NASDAQ: TSLA), and emerging social media plays such as Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN).

  • Newsfile

    Novavax Update

    Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Novavax To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - October 24, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novavax ("Novavax, Inc." or the "Company") (NASDAQ: NVAX).If you suffered losses exceeding $200,000 investing in Novavax stock or options and would like to discuss your


    INVESTOR ALERT - Labaton Sucharow is Investigating Novavax, Inc. (NASDAQ:NVAX) for Potential Securities Violations

    NEW YORK, NY / ACCESSWIRE / October 22, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential violations of the federal securities laws by Novavax, Inc.On October 19, 2021, after the market closed, Politico published an article titled, "'They Rushed the Process': Vaccine Maker's woes hamper global inoculation campaign," alleging manufacturing and purity problems in Novavax's process to produce Covid-19 vaccinations for COVAX, an in